Multiple protein 4
Introduction
Studies on red cells from patients with abnormal red cell morphology and clinically significant hemolytic anemia have focused on the structure and function of the "membrane skeleton,' a highly organized network of proteins supporting the inner surface of the cell membrane. Several red cell disorders, including hereditary spherocytosis and hereditary elliptocytosis (HE),' can result from disruption ofmembrane function by PBGD, porophobilinogen deaminase; PCR, polymerase chain reaction; RFLPs, restriction fragment polymorphisms. mutation of the gene(s) for major membrane skeletal proteins including protein 4.1, a-and f-spectrin, ankyrin, and band 3 (1) .
Although most of these skeletal proteins were originally thought to be restricted to erythroid cells, it is now known that closely homologous proteins are also found in most nonerythroid cell types. Interestingly, the nonerythroid homologs often vary with respect to size, sequence, or subcellular location compared to the red cell forms. These different but homologous forms (isoforms) ofmembrane proteins may arise as products ofdistinct genes, or by differences in expression of a single gene in erythroid versus nonerythroid cells. One well-known mechanism for differential gene expression is alternative premRNA splicing, a process by which a single gene can generate different isoforms in different tissues.
Protein 4.1 is a key membrane skeletal protein which plays an important role in determining red cell shape and integrity through specific interactions with other skeletal and membrane components. The major form of protein 4 .1 in red cells is a polypeptide of -80 kD, while nonerythroid cells contain a heterogeneous array of4.1 polypeptides that range in size from 30 to 210 kD (2) . Despite the size and structural variations among these proteins, all appear to be encoded by a single large gene (> 100 kb) (3) . Isoform variation is generated by alternative splicing ofthe 4.1 pre-mRNA transcribed from this gene, a complex process in which discrete exons are either spliced in (included) or spliced out (deleted) to produce an array of mature 4.1 messenger RNAs that can be translated into different protein isoforms (Fig. 1 A) (4) (5) (6) (7) . In addition, either of two potential translation initiation sites (denoted by the trinucleotide AUG) can be used depending on whether the upstream (more 5') or downstream sites are included in the mature mRNA (5, 7) (Fig. 1 B) . Reticulocyte 4.1 mRNAs possess only the downstream AUG and can synthesize only the 80-kD red cell isoform, while nucleated erythroid progenitors and nonerythroid cells also contain the upstream initiation sites and synthesize larger protein 4.1 isoforms having an elongated NH2-terminal sequences (Fig. 1 B) .
Mutations in the protein 4.1 gene result in hereditary elliptocytosis. To date, mutations that result in elongated or shortened 4.1 polypeptides (8) (9) (10) (11) (12) or deficiency of red cell protein 4.1 (10, (13) (14) (15) (16) (17) have been described. We have previously reported that in an Algerian family, several siblings suffer from HE and severe hemolytic anemia caused by the complete absence oferythroid protein 4. 1. These patients, the offspring ofa consanguinous marriage, were homozygous for a structural rearrangement of the protein 4.1 gene located around the downstream AUG codon (3) . Surprisingly, although the same gene encodes protein 4 Jolla, CA) and sequenced using Sequenase (U.S. Biochemical Corp., Cleveland, OH) according to the manufacturer's specifications. Primers used in this study were as follows: sense strand = 5'-CAAAA-CAGACCCATCTTTGGATCTTCATTC-3'; antisense strand = 5'-TGTAAAATTCCAAGGGACACCACGAACCTG-3'.
Results
Immunological detection ofprotein 4.1 in nonerythroid tissues. We have previously shown that protein 4.1 is completely absent from the HE patient's red cells ( 15 ). To test for the presence of protein 4.1 in the patient's nonerythroid cells, we stained cultured fibroblasts with antibodies directed against different domains of the protein. Fig. 2 shows phase contrast photomicrographs of normal (A) and patient (D) fibroblasts, as well as immunofluorescence images of these cells stained with two different anti-4. 1 antibodies. Antibody directed against a COOH-terminal domain of the protein (anti 24-2) fluorescently labeled both fibroblast samples (Fig. 2, B and E), indicating that patient fibroblasts do contain protein 4.1 isoform(s). Furthermore, antibody directed against the NH2-terminal extension (anti-N-1) also stained these fibroblasts (Fig.  2, C and F) . This latter result demonstrates that the protein 4.1 isoforms present in patient fibroblasts arose from translation initiation at the upstream AUG, and predicts that they contain species larger than the 80-kD isoforms found in red cells.
To examine the molecular masses of protein 4.1 isoforms expressed in patient red cells and fibroblasts, we used an immunoblotting procedure on proteins that had been size-fractionated by PAGE (Fig. 3) bands, representing alternatively spliced mRNA isoforms designated a-e (see Fig. 1 A) . The most abundant isoform in normal cells is isoform b, which includes the downstream AUG. Normal cells also contain small amounts of 4.1 mRNA which has deleted the downstream AUG as a consequence ofalternative splicing (isoform e). In contrast, 4.1 cDNA amplified from the HE patient yielded only PCR product e (Fig. 4 B, lane 2) . DNA sequence analysis of this product revealed a 31 8-nucleotide deletion caused by the absence oftwo exons, including the one encoding the downstream AUG. Since this downstream site is required for translation initiation in late erythroid cells, the HE reticulocytes are incapable of synthesizing 80-kD protein 4.1. The structure of protein 4.1 mRNA was next examined in both normal and HE fibroblasts, using an identical PCR strategy to amplify the region around the downstream AUG. As with reticulocytes, the normal RNA sample yielded predominantly isoform b (Fig. 4 B, lane 3) , while the patient sample exhibited only isoform e lacking the downstream AUG (Fig. 2  B, lane 4) . When PCR was repeated using oligonucleotide primers specific for the upstream AUG, normal and patient fibroblast 4.1 mRNA amplified equally well, suggesting that they retain the potential to express high molecular 4.1 isoforms (not shown). These results, loss of the downstream AUG coupled with retention of the upstream site in 4.1 mRNA, are consistent with the immunological data showing that patient fibroblasts have selectively lost expression of 80-kD isoforms, but not higher molecular mass isoforms (Fig. 3) .
Discussion
The protein 4.1 gene is differentially regulated by a complex pattern of RNA splicing, as illustrated in Fig. 1 plays an important role in maintaining red cell morphology and plasticity, the functions of the other 4.1 isoforms are not yet precisely known. Immunostaining of nucleated cells has shown that the larger isoforms appear localized to specific intranuclear structures including the centriole, and may be a component ofa nuclear skeleton ( 19) . In contrast to the sole manifestation of hemolytic anemia produced by 4.1 deficiency in red cells, we speculate that deficiency of nuclear 4.1 isoforms may disrupt some vital function required for maturation of all nucleated cells, and that homozygosity for such a mutation would be incompatible with life.
In the patient we studied, a gene rearrangement around the downstream AUG resulted in selective loss of 80-kD isoforms of4.1 in erythroid and nonerythroid cells. Fig. 5 illustrates how the mutation produces this unusual phenotype. The upper panel represents a portion of the 4.1 gene containing the two translation initiation sites in two different 5' exons. The sequences shaded in grey are rearranged in the mutant gene and deleted from the corresponding mature mRNAs shown in the lower panel. Since the deletion encompasses only one of the two potential translation initiation sites, an isoform-specific deficiency arises in which 80-kD protein 4.1 synthesis is blocked, but other isoforms translated from the upstream site are unaffected. Reticulocyte 4.1 mRNA is not translatable because of the absence of a functional translation initiation site (the upstream site being excluded by splicing, the downstream site by mutation). Terminally differentiating red cells are thus completely deficient in the 80-kD 4.1 protein required to mechanically stabilize the red cell membrane, leading to the altered elliptical morphology and hemolytic anemia characteristic of HE. In contrast, fibroblast 4.1 mRNA contains the upstream AUG and retains the capability to synthesize other isoform(s) bearing an extended NH2 terminus. These isoforms probably retain most of the protein 4.1 domains required for nuclear function.
The precise nature of the mutation in the protein 4.1 gene responsible for the unusual phenotype is not known. In a previous study, we showed that several restriction fragment length polymorphisms (RFLPs) cosegregated with HE and protein 4.1 deficiency in this family (3). These RFLPs, which have not been observed in other normal individuals, mapped to a 5' region of the gene around the downstream AUG. The most obvious interpretation of these results was that the mutant 4.1 gene had undergone a rearrangement, possibly involving a genomic deletion ofone or more exons. Using radiolabeled single exon probes for hybridizing to genomic Southern blots, we have recently determined that the exon encoding the downstream AUG, although detected within an abnormal restriction fragment, is not deleted (results not shown). Nondeletional mechanisms that might produce an "exon-skipping" phenotype include at least two obvious possibilities. First, a gross genomic inversion spanning the affected exons would alter the regional restriction map and place the exons in an antisense orientation with respect to the remainder of the gene. During pre-mRNA processing, exons in the inverted region would be skipped because the splicing signals would all be inverted as well. Alternatively, even a relatively small deletion/ rearrangement in an adjacent intron could, if it altered critical splicing signal(s), block splicing of neighboring exons and produce the same exon skipping phenotype. In the case of the downstream AUG, this exon is skipped at a low frequency, even during normal 4.1 pre-mRNA processing, and a splicing mutation could alter the balance so as to produce a very high frequency (10, (13) (14) (15) (16) (17) . Generally these are only partial deficiencies and thus affected individuals do not suffer the severe hemolytic anemia observed in the homozygous deficient Algerian family members. In the other class of mutation, 4.1 (+ )HE, 4.1 protein is present but is qualitatively altered in structure (8) (9) (10) (11) 20) . Biophysical studies show that both classes of mutation decrease membrane stability and deformability ( 1 1, 12, 15 (8) (9) (10) (11) 20 (28, 29) . In the case of (3- spectrin ( 21), this protein is abnormal or deficient in a subset of human elliptocytosis patients and in the mouse mutant known as jaundiced. Since the f-spectrin gene is spliced differently in erythroid versus muscle cells, the potential exists for regulatory mutations which could exhibit unusual phenotypes.
Beyond the red cell membrane, alternative splicing has been described in a wide variety of other genes, some of which are also differentially expressed in erythroid vs. nonerythroid cells. One of the first reported examples involves the gene encoding porphobilinogen deaminase (PBGD), the third enzyme in the heme biosynthetic pathway. A variant form of acute intermittent porphyria, characterized by normal red cell levels of the PBGD enzyme, can be generated by a mutation having an effect converse to that described in this paper. That is, expression of an upstream AUG required for translation of nonerythroid PBGD is disrupted, while a downstream AUG used in erythroid cells is expressed normally (30, 31 ) .
Many other variations on this theme are likely to be uncovered in the future, as the list of known alternatively spliced genes has grown enormously in the past few years. Vital intracellular structural proteins such as tropomyosin (32) , myosin (33) , and troponin (34), cell surface integrin (35) and growth factor receptors (36) , cellular proto-oncogenes (37) (38) (39) 
